Antibiotics Market Deals - How and Why Companies Enter?

Text-only Preview

Antibiotics Partnering Terms and Agreements, a January 2015 report available at
ReportsnReports.com industry research reports col ection.
The report provides comprehensive understanding and unprecedented access to the
antibiotic partnering deals and agreements entered into by the world's leading healthcare
companies.
The report provides an understanding and access to the antibiotics partnering deals and
agreements entered into by the world's leading healthcare companies.
Trends in antibiotics partnering deals
Disclosed headlines, up fronts, milestones and royalties by stage of development
Antibiotics partnering c ontract documents
Top antibiotics deals by value
The report provides a detailed understanding and analysis of how and why companies enter
antibiotics partnering deals. The majority of deals are early development stage whereby the
licensee obtains a right or an option right to license the licensors antibiotics technology or
product candidates. These deals tend to be multicomponent, starting with col aborative
R&D, and commercialization of outcomes.
Buy a copy of report @
http://www.reportsnreports.com/Purchase.aspx?name=242995. (Single User of
this Report is US $1995)
This report provides details of the latest antibiotics agreements announced in the healthcare
sectors, covering:
Antibiotics
Aminoglycosides
Cephalosporin
Clindamycin
Macrolides
Penicil in
Quinolones
Sulfonamides
Tetracycline
Understanding the flexibility of a prospective partner's negotiated deals terms provides
critical insight into the negotiation process in terms of what you can expect to achieve
during the negotiation of terms. Whilst many smal er companies wil be seeking details of
the payments clauses, the devil is in the detail in terms of how payments are triggered -
contract documents provide this insight where press releases and databases do not.
This report contains over 150 links to online copies of actual antibiotics deals and contract
documents as submitted to the Securities Exchange Commission by companies and their
partners. Contract documents provide the answers to numerous questions about a
prospective partner's flexibility on a wide range of important issues, many of which wil have
a significant impact on each party's ability to derive value from the deal.

Get
discount
on
the
Report
@
http://www.reportsnreports.com/contacts/Discount.aspx?name=242995.
Contract documents provide the answers to numerous questions about a prospective
partner's flexibility on a wide range of important issues, many of which wil have a
significant impact on each party's ability to derive value from the deal.
For example, analyzing actual company deals and agreements al ows assessment of the
fol owing:
1. What is actual y granted by the agreement to the partner company?
2. What exclusivity is granted?
3. What are the precise rights granted or optioned?
4. What is the payment structure for the deal?
5. How are sales and payments audited?
6. What is the deal term?
7. How are the key terms of the agreement defined?
8. How are IPRs handled and owned?
9. Who is responsible for commercialization?
10. Who is responsible for development, supply, and manufacture?
11. How is confidentiality and publication managed?
12. How are disputes to be resolved?
13. Under what conditions can the deal be terminated?
14. What happens when there is a change of ownership?
15. What sublicensing and subcontracting provisions have been agreed?
16. Which boilerplate clauses does the company insist upon?
17. Which boilerplate clauses appear to differ from partner to partner or deal type to
deal type?
18. Which jurisdiction does the company insist upon for agreement law?
The initial chapters of this report provide an orientation of antibiotics dealmaking and
business activities. Chapter 1 provides an introduction to the report, whilst chapter 2
provides an overview of the trends in antibiotics dealmaking since 2009, including details of
average headline, upfront, milestone and royalty terms.
Chapter 3 provides a review of the leading antibiotics deals since 2009. Deals are listed by
headline value, signed by big pharma, most active big pharma, and most active of al
biopharma companies. Where the deal has an agreement contract published at the SEC a
link provides online access to the contract.
Chapter 4 provides a comprehensive listing of the top 50 big pharma companies with a brief
summary fol owed by a comprehensive listing of antibiotics deals, as wel as contract
documents available in the public domain. Where available, each deal title links via Weblink
to an online version of the actual contract document, providing easy access to each contract
document on demand.
Chapter 5 provides a comprehensive listing of the top 50 big biotech companies with deal
announced along with a brief summary fol owed by a comprehensive listing of antibiotics
deals, as wel as contract documents available in the public domain. Where available, each
deal title links via Weblink to an online version of the actual c ontract document, providing
easy access to each contract document on demand.

Chapter 6 provides a comprehensive and detailed review of antibiotics partnering deals
signed and announced since 2009, where a contract document is available in the public
domain. The chapter is organized by company A-Z, stage of development at signing, deal
type (col aborative R&D, co-promotion, licensing etc) and specific therapy focus. Each deal
title links via Weblink to an online version of the deal record and where available, the
contract document, providing easy access to each contract document on demand.
Chapter 7 provides a comprehensive and detailed review of antibiotics partnering deals
signed and announced since 2009 organized by antibiotics technology focus. The chapte r
includes deals listed by antibiotics and broken down into individual type of antibiotics -
aminoglycosides, cephalosporin, clindamycin, macrolides, metronidazole, penicil in,
quinolones and tetracycline. Each deal title links via Weblink to an online version of the deal
record and where available, the contract document, providing easy access to each contract
document on demand.
The report also includes numerous tables and figures that il ustrate the trends and activities
in antibiotics partnering and dealmaking since 2009.
In addition, a comprehensive appendix is provided organized by antibiotics partnering
company A-Z , stage of development, deal type and therapy focus, deal type definitions and
antibiotics partnering agreements example. Each deal title links via Weblink to an online
version of the deal record and where available, the contract document, providing easy
access to each contract document on demand.
Inquire
Before
buying
the
Report
@
http://www.reportsnreports.com/contacts/InquiryBeforeBuy.aspx?name=24299
5.
In conclusion, this report provides everything a prospective dealmaker needs to know about
partnering in the research, development and commercialization of antibiotics technologies
and products.
Report scope
Antibiotics Partnering Terms and Agreements is intended to provide the reader with an in-
depth understanding and access to antibiotics trends and structure of deals entered into by
leading companies worldwide.
Antibiotics Partnering Terms and Agreements include:
Trends in antibiotics dealmaking in the biopharma industry since 2009
Analysis of antibiotics deal structure
Access to headline, upfront, milestone and royalty data
Case studies of real-life antibiotics deals
Access to over 150 antibiotics deal records and contract documents where available
The leading antibody deals by value since 2009
Most active antibiotics dealmakers since 2009
The leading antibiotics partnering resources

In Antibiotics Partnering Terms and Agreements, the available contracts are listed by:
Company A-Z
Headline value
Stage of development at signing
Deal component type
Specific therapy and technology target
Each deal title links via Weblink to an online version of the deal record and where available,
the contract document, providing easy access to each contract document on demand.
Benefits
Antibiotics Partnering Terms and Agreements provide the reader with the fol owing key
benefits:
In-depth understanding of antibiotics deal trends since 2009
Access to headline, upfront, milestone and royalty data
Analysis of the structure of antibiotics agreements with numerous real life case
studies
Comprehensive access to over 150 antibiotics deals entered into by the world's
biopharma companies, together with real world clause examples and contracts where
available
Ful listing of antibiotics deals by company A-Z, deal value, phase of development,
deal type, and therapy focus
Identify leading antibiotics deals by value since 2009
Identify the most active antibiotics dealmakers since 2009
Detailed access to actual antibiotics contracts enter into by the leading fifty big
pharma and big biotech companies
Insight into the terms included in a antibiotics agreement, together with real world
clause examples
Understand the key deal terms companies have agreed in previous deals
Undertake due diligence to assess suitability of your proposed deal terms for partner
companies
Browse Other Reports by Current Partnering:
Manufacturing and Supply Partnering Terms and Agreements in Pharma, Biotech
and Diagnostics : The Manufacturing and Supply Partnering Terms and Agreements in
Pharma, Biotech and Diagnostics report provides comprehensive understanding and
unprecedented access to the manufacturing and supply agreements entered into by the
world's biopharma companies. The report provides a detailed understand and analysis of
how and why companies enter manufacturing and supply deals.
Infectious Vaccines Partnering Terms and Agreements : The report contains a
comprehensive listing of al infectious vaccines partnering deals announced since January
2009, including financial terms where available, including over 500 links to online deal
records of actual infectious vaccines partnering deals as disclosed by the deal parties. In

addition, where available, records include contract documents as submitted to the Securities
Exchange Commission by companies and their partners.
Contact [email protected]/ Cal +1 888 391 5441 for further information on
"Antibiotics Partnering Terms and Agreements" report OR for any other market research and
intel igence needs you may have for your business.